Emergent BioSolutions cuts 2026 revenue and EBITDA guidance as Q3 sales fall 52%Nov 2Quarterly updateAmgenAprea Therapeutics
FDA approves Teva's Degevma, a denosumab biosimilar-type productSep 25Regulatory decisiondenosumabdenosumab-adet
Sign inSign in